Tag Archives: Industry Analysis

Recommended Reading from BIOtechNOW

Partnering Meetings

We hope the dust has settled from Boston’s International Convention, and you’re ready for a busy fall schedule! Here’s just a quick post on some recent articles that have been published on BIOtechNOW that’s worth a read. 2012 Fall Event Preview – A recap of BIO’s upcoming BD events, among others. 2012 BIO Convention in China: Highlighting Cross-Border Partnering in Biotechnology – Take a deeper look at the 2nd Annual BIO China event. We’re also Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

Index-Perfomance-June-2012-thumb

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Business Confidence with the RFS Under Attack

biofuels-btn

This week, Biofuels Digest and BIO launched the quarterly Bioenergy Business Outlook Survey. Results from the first quarter of 2012 showed that industry optimism remained high earlier in the year, even though companies still reported difficulty in raising the capital needed for ongoing research and development and construction of demonstration and commercial biorefineries. Now that the petroleum refiners have launched a multi-million dollar pr campaign against the biofuel industry, it will be interesting to take Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Only a Few Public Biotechs are Profitable, but There are More of Them Today

Of the 294 biotechs trading on public exchanges today, 248 (84%) focus on drug development. Of these 248 in the biopharmaceutical space, 81, or 33% have a drug approved. Only 32 (13%) had both a product on the market and positive net income in 2011. However, this 13% represents a significant jump from the 7.5% with positive net income we calculated for 2009. Note that this comes over a time frame in which a few profitable companies were Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,